These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1119 related articles for article (PubMed ID: 8804140)

  • 21. Methods for modelling change in cluster randomization trials.
    Klar N; Darlington G
    Stat Med; 2004 Aug; 23(15):2341-57. PubMed ID: 15273952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Brookline Early Education Project: a 25-year follow-up study of a family-centered early health and development intervention.
    Palfrey JS; Hauser-Cram P; Bronson MB; Warfield ME; Sirin S; Chan E
    Pediatrics; 2005 Jul; 116(1):144-52. PubMed ID: 15995045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imputation strategies for missing continuous outcomes in cluster randomized trials.
    Taljaard M; Donner A; Klar N
    Biom J; 2008 Jun; 50(3):329-45. PubMed ID: 18537126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraclass correlation coefficients for cluster randomized trials in primary care: the cholesterol education and research trial (CEART).
    Parker DR; Evangelou E; Eaton CB
    Contemp Clin Trials; 2005 Apr; 26(2):260-7. PubMed ID: 15837446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matching in epidemiologic studies: validity and efficiency considerations.
    Kupper LL; Karon JM; Kleinbaum DG; Morgenstern H; Lewis DK
    Biometrics; 1981 Jun; 37(2):271-91. PubMed ID: 7272415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.
    Parienti JJ; Kuss O
    Contemp Clin Trials; 2007 May; 28(3):316-23. PubMed ID: 17110172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
    Cook RJ; Wei W
    Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials:randomization before consent.
    Armstrong PW; Watts DG
    Biomedicine; 1981 Sep; 34(2):65-6. PubMed ID: 7284544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size estimation for GEE method for comparing slopes in repeated measurements data.
    Jung SH; Ahn C
    Stat Med; 2003 Apr; 22(8):1305-15. PubMed ID: 12687656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the catch-up time method for analyzing cancer screening trials.
    Etzioni R; Self SG
    Biometrics; 1995 Mar; 51(1):31-43. PubMed ID: 7766785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
    Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
    J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies with group treatments required special power calculations, allocation methods, and statistical analyses.
    Faes MC; Reelick MF; Perry M; Olde Rikkert MG; Borm GF
    J Clin Epidemiol; 2012 Feb; 65(2):138-46. PubMed ID: 21856120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study.
    Schoenfeld DA; Gelber RD
    Biometrics; 1979 Dec; 35(4):825-9. PubMed ID: 526527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.